Contamination Gene Gene Therapy 
Roots Analysis
JANUARY 27, 2025
The American Society of Gene and Cell Therapy (ASGCT) defines cell therapy as a therapeutic modality that involves the administration of either normal or modified cells to patients for the treatment of various diseases. Contamination is a key concern when it comes to manufacturing cell therapy products.
pharmaphorum
MARCH 22, 2022
The challenges posed to manufacture these new therapies falls in line with the complexity of the therapies themselves, with a number of breakthroughs in the next generation of therapies being particularly challenging to produce at scale, such as cell and gene therapies. Taking manufacturing to the next level.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Advarra
JULY 28, 2022
This article explores how these tools work and why biosafety cabinets are preferred in research involving cell and gene therapies. Use of hazardous materials in a clean bench can increase the risk of occupational exposure and contamination of the room in which the work is being done. What is a Biosafety Cabinet?
FDA Law Blog
NOVEMBER 1, 2022
USP opened the workshop with a description of its organization, each of its applicable standards for advanced therapies, including its standards (general chapters) <1046> Cell and Tissue Based Products and <1047> Gene Therapy Products, and its microbial related chapters open for comment: <74> Solid Phase Cytometry-Based Rapid (..)
Roots Analysis
SEPTEMBER 20, 2023
In this form of therapy, patients are injected with living and intact human cells that are deemed to be capable of providing therapeutic benefit. It is important to highlight that cell and gene therapies have been used to treat an array of medical conditions for which no other treatments are available.
Roots Analysis
APRIL 15, 2024
These complex entities, such as antibodies, antibody drug conjugates, cell therapies, gene therapies, and therapeutic proteins, are highly specific molecules that are designed to precisely target biomarkers associated with a particular disease pathway.
Roots Analysis
AUGUST 30, 2023
Further, in the same year, nearly half of the biologic approvals were allotted to novel class of modalities, including antibody drug conjugates (ADCs), bispecific antibodies, cell therapies and gene therapies. Specifically, advancements in niche segments is expected to culminate in accelerated growth of the biologics market.
Expert insights. Personalized for you.
40 
Let's personalize your content